Tomislav Dragovich

4.4k total citations
80 papers, 2.3k citations indexed

About

Tomislav Dragovich is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Tomislav Dragovich has authored 80 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Tomislav Dragovich's work include Pancreatic and Hepatic Oncology Research (34 papers), Colorectal Cancer Treatments and Studies (23 papers) and Cancer Genomics and Diagnostics (12 papers). Tomislav Dragovich is often cited by papers focused on Pancreatic and Hepatic Oncology Research (34 papers), Colorectal Cancer Treatments and Studies (23 papers) and Cancer Genomics and Diagnostics (12 papers). Tomislav Dragovich collaborates with scholars based in United States, Spain and Australia. Tomislav Dragovich's co-authors include Amanda F. Baker, Charles M. Rudin, Craig B. Thompson, Daniel D. Von Hoff, Cecilia M. Fenoglio‐Preiser, Sandra Kurtin, James L. Abbruzzese, Garth Powis, Ramesh K. Ramanathan and David S. Mendelson and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Research.

In The Last Decade

Tomislav Dragovich

78 papers receiving 2.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomislav Dragovich United States 24 1.1k 1.0k 548 444 270 80 2.3k
Lila Adnane United States 6 1.0k 0.9× 1.1k 1.1× 582 1.1× 440 1.0× 168 0.6× 7 2.6k
Heike Richly Germany 20 1.2k 1.0× 1.1k 1.0× 736 1.3× 380 0.9× 181 0.7× 56 2.4k
José A. López-Martín Spain 28 1.3k 1.1× 824 0.8× 601 1.1× 352 0.8× 314 1.2× 123 2.4k
Kyle D. Holen United States 31 1.8k 1.6× 1.1k 1.1× 479 0.9× 372 0.8× 451 1.7× 126 3.2k
Herman Burger Netherlands 28 1.3k 1.1× 1.2k 1.1× 330 0.6× 246 0.6× 218 0.8× 45 2.6k
Shundong Cang China 21 779 0.7× 1.4k 1.3× 679 1.2× 485 1.1× 97 0.4× 80 2.3k
Takayuki Kimura Japan 19 924 0.8× 522 0.5× 464 0.8× 315 0.7× 177 0.7× 66 2.2k
Igor Astsaturov United States 32 1.1k 1.0× 1.2k 1.2× 496 0.9× 512 1.2× 411 1.5× 97 2.7k
Agustin A. García United States 31 1.5k 1.4× 1.1k 1.0× 681 1.2× 392 0.9× 339 1.3× 114 3.1k
Bryson W. Katona United States 23 958 0.9× 905 0.9× 194 0.4× 449 1.0× 246 0.9× 100 2.1k

Countries citing papers authored by Tomislav Dragovich

Since Specialization
Citations

This map shows the geographic impact of Tomislav Dragovich's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomislav Dragovich with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomislav Dragovich more than expected).

Fields of papers citing papers by Tomislav Dragovich

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomislav Dragovich. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomislav Dragovich. The network helps show where Tomislav Dragovich may publish in the future.

Co-authorship network of co-authors of Tomislav Dragovich

This figure shows the co-authorship network connecting the top 25 collaborators of Tomislav Dragovich. A scholar is included among the top collaborators of Tomislav Dragovich based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomislav Dragovich. Tomislav Dragovich is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Chang, John C. S., et al.. (2021). Skeletal metastases in advanced pancreatic ductal adenocarcinoma: a retrospective analysis. Journal of Gastrointestinal Oncology. 12(2). 455–463. 7 indexed citations
3.
Kiebish, Michael A., Viatcheslav R. Akmaev, Rangaprasad Sarangarajan, et al.. (2019). Abstract 4945: Project Survival: Engineering a phenomic and artificial intelligence driven precision medicine biomarker pipeline for pancreatic adenocarcinomas. Cancer Research. 79(13_Supplement). 4945–4945. 1 indexed citations
4.
Youssef, Alexey, et al.. (2018). Thrombotic Thrombocytopenic Purpura due to Checkpoint Inhibitors. SHILAP Revista de lepidopterología. 2018. 1–4. 30 indexed citations
5.
Frick, Jacob, et al.. (2018). Chemotherapy re-challenge response rate in metastatic colorectal cancer. Journal of Gastrointestinal Oncology. 9(4). 679–686. 10 indexed citations
6.
Lenz, Heinz‐Josef, Eric Van Cutsem, María Luisa Limón, et al.. (2018). Durable clinical benefit with nivolumab (NIVO) plus low-dose ipilimumab (IPI) as first-line therapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Annals of Oncology. 29. viii714–viii714. 68 indexed citations
7.
Kundranda, Madappa N., Jiaxin Niu, Boris G. Naraev, et al.. (2018). Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma. OncoTargets and Therapy. Volume 11. 7095–7107. 191 indexed citations
8.
Kundranda, Madappa N., Alexander Köenig, Kirsten Bornemann-Kolatzki, et al.. (2017). Tumor cell-free DNA copy number instability compared to CA19-9 as an early predictor of response to systemic therapy in pancreatic ductal adenocarcinoma (PDAC).. Journal of Clinical Oncology. 35(15_suppl). e14524–e14524. 1 indexed citations
9.
10.
Dragovich, Tomislav, Daniel A. Laheru, Farshid Dayyani, et al.. (2014). Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001). Cancer Chemotherapy and Pharmacology. 74(2). 379–387. 56 indexed citations
11.
Saif, Muhammad Wasif, Charles Erlichman, Tomislav Dragovich, et al.. (2013). Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 71(5). 1345–1355. 25 indexed citations
12.
Borad, Mitesh J., Shantan Reddy, Hope E. Uronis, et al.. (2012). Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer. Cancer Research. 72(8_Supplement). LB–121. 8 indexed citations
13.
14.
Ramanathan, Ramesh K., James L. Abbruzzese, Tomislav Dragovich, et al.. (2010). A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemotherapy and Pharmacology. 67(3). 503–509. 104 indexed citations
15.
Dragovich, Tomislav, Howard A. Burris, Patrick J. Loehrer, et al.. (2008). Gemcitabine Plus Celecoxib in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology. 31(2). 157–162. 59 indexed citations
16.
Chiorean, E. Gabriela, Tomislav Dragovich, John Hamm, et al.. (2007). A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma. Cancer Chemotherapy and Pharmacology. 61(6). 1019–1026. 12 indexed citations
17.
Dragovich, Tomislav, Mark S. Huberman, Daniel D. Von Hoff, et al.. (2006). Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial. Cancer Chemotherapy and Pharmacology. 60(2). 295–303. 40 indexed citations
18.
Dragovich, Tomislav, David S. Mendelson, Sandra Kurtin, et al.. (2006). A Phase 2 trial of the liposomal DACH platinum L-NDDP in patients with therapy-refractory advanced colorectal cancer. Cancer Chemotherapy and Pharmacology. 58(6). 759–764. 106 indexed citations
19.
Dragovich, Tomislav, David S. Mendelson, Axel Hoos, et al.. (2003). 268 A phase II trial of aroplatin (L-NDDP), a liposomal DACH platinum, in patients with metastatic colorectal cancer (CRC) - a preliminary report. European Journal of Cancer Supplements. 1(5). S82–S83. 9 indexed citations
20.
Dragovich, Tomislav, Charles M. Rudin, & Craig B. Thompson. (1998). Signal transduction pathways that regulate cell survival and cell death. Oncogene. 17(25). 3207–3213. 163 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lila Adnane Breakdown of academic impact, for papers by Heike Richly Breakdown of academic impact, for papers by José A. López-Martín Breakdown of academic impact, for papers by Kyle D. Holen Breakdown of academic impact, for papers by Herman Burger Breakdown of academic impact, for papers by Shundong Cang Breakdown of academic impact, for papers by Takayuki Kimura Breakdown of academic impact, for papers by Igor Astsaturov Breakdown of academic impact, for papers by Agustin A. García Breakdown of academic impact, for papers by Bryson W. Katona
Rankless by CCL
2026